Mechanism of Action | ENTRESTO® (sacubitril/valsartan)

ENTRESTO^® is designed specifically to treat heart failure (HF)^1-3

The only treatment in the HF landscape of its kind, ENTRESTO has a dual MOA that targets 2 complementary HF pathways^1-3

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.¹

Definitions & References

Definitions
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; MOA, mechanism of action; RAS, renin-angiotensin system.

References
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
2. Hasenfuss G, Mann DL. Pathophysiology of heart failure. In: Mann DL, Zipes DP, Libby P, Bonow RO, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 10th ed. Elsevier Saunders; 2015:1-116.
3. Hilal-Dandan R. Renin and angiotensin. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th ed. McGraw-Hill; 2011:721-744.

ENTRESTO^® is designed specifically to treat heart failure (HF)^1-3

The only treatment in the HF landscape of its kind, ENTRESTO has a dual MOA that targets 2 complementary HF pathways^1-3

Important Safety Information

Indication

Definitions & References

ENTRESTO® is designed specifically to treat heart failure (HF)1-3

The only treatment in the HF landscape of its kind, ENTRESTO has a dual MOA that targets 2 complementary HF pathways1-3

Definitions & References

ENTRESTO^® is designed specifically to treat heart failure (HF)^1-3

The only treatment in the HF landscape of its kind, ENTRESTO has a dual MOA that targets 2 complementary HF pathways^1-3